Розділ : Новини

Головна/Архів статей "Новини" (Page 6)

New method to grow and transplant muscle stem cells holds promise as muscular dystrophy therapy

Satellite cells are stem cells found in skeletal muscles. While transplantation of such muscle stem cells can be a potent therapy for degenerative muscle diseases such as Duchenne muscular dystrophy, these cells tend to lose their transplantation efficiency when cultured in vitro. In the study, published in the current issue of the Journal of Neuromuscular Diseases, researchers have found that treating these stem cells with leukemia inhibitory factor (LIF) effectively maintains the undifferentiated state of the satellite cells and enhances their transplantation efficiency.

Продовжити

Double stem cell transplant improves outcome for children with deadly form of cancer

Results of a recent clinical trial show that adding a second autologous stem cell transplant (which uses the patient’s own stem cells) to standard therapy improves outcomes for children with neuroblastoma. Neuroblastoma is a rare cancer that most commonly affects children age 5 or younger. Historically, less than half of children with high-risk neuroblastoma live five or more years after diagnosis.

Продовжити

Cells engineered from muscular dystrophy patients offer clues to variations in symptoms

Researchers have inadvertently found a way to make human muscle cells bearing genetic mutations from people with Duchenne muscular dystrophy (DMD). The finding should shed light on how subtle genetic differences among DMD patients produce symptoms with a wide range of severity and disability. The cells, they say, could also be used to test new therapies.

Продовжити

New, high risk stem cell transplant method might provide long-term MS relief

A new clinical trial shows how an intensive procedure that completely wipes out the immune system and regenerates a new one with the help of blood stem cells can significantly reduce inflammation in patients with early, aggressive multiple sclerosis (MS) and lead to lasting recovery. The trial involved 24 participants who were followed for up to 13 years and is the first to show a complete, long-term suppression of inflammation in patients with MS.

Продовжити